Pharmaceutical Company

FDA Recalls Half a Million Bottles of Blood Pressure Drug

Pharma company recalls 580K bottles of blood pressure meds, according to FDA

A pharmaceutical company has initiated a voluntary recall of more than half a million bottles of its blood pressure medication distributed in the U.S., after finding that the bottles contained higher than acceptable levels of a carcinogen.

· 19h · on MSN

580,000 bottles of a blood pressure drug recalled over cancer risk

· 1d · on MSN

Blood pressure medications recalled due to carcinogen concern

· 12h

FDA says drugmakers have recalled a blood pressure medicine tainted with a cancer-causing chemical

The U.S. Food and Drug Administration says drug makers have recalled more than a half-million bottles of the blood pressure medication prazosin hydrochloride over concerns it may include a cancer-cau...

· 1d

Blood pressure drug recalled over cancer concerns. What it means for Ohioans

· 15h

Blood pressure medication recalled over potential carcinogen: What to know

· 12h

Teva Pharmaceuticals recalls blood pressure medication. How to check your medication

The recall involves more than 580,000 prazosin hydrochloride capsules distributed by Teva Pharmaceuticals.

· 23h

FDA: Once Again A Blood Pressure Medication Recall For Cancer Concerns

· 16h

FDA warns this blood pressure medication may have cancer-causing chemicals. See recall list

Top Pharmaceutical Companies Shaping The Future Of Healthcare

Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in GLP-1s, oncology, and pipeline strength.

3don MSN

Global pharmaceutical firm chooses Bridgewater for new corporate offices

This article originally appeared on MyCentralJersey.com: Global pharmaceutical firm chooses Bridgewater for new corporate offices BRIDGEWATER – Gov. Phil Murphy attended the opening of corporate offices for an international pharmaceutical company in the Somerset Corporate Center.

Virginia Business

AstraZeneca, Eli Lilly, Merck commit $120M to Virginia pharma training

AstraZeneca, Eli Lilly and Merck committed $120 million to develop an advanced pharmaceutical manufacturing training center in Central Virginia.

13h

Alnylam Pharmaceuticals: Q3 Earnings Review - A Sensational Year Reaches Its Peak

Alnylam Pharmaceuticals, Inc. is rated Hold due to high expectations, competitive threats, and revenue expansion. Learn more about ALNY stock here.

The Reynolds Center for Business Journalism

How much is your baby’s life worth? ProPublica duo show how pharmaceutical companies justify sky-high drug prices

The reporting duo demonstrate how drugmakers exploit public funding and legal loopholes to turn high profits, while justifying the price tag.

1mon

Swiss pharma companies eye follow up to Pfizer-US pricing deal, business lobby says

GENEVA (Reuters) -Swiss drugmakers could strike their own deals with the U.S. after President Donald Trump's push to lower prescription drug prices led to an accord with Pfizer in exchange for tariff relief,

New Jersey Business Magazine

Pharma Firm Lupin Limited Inaugurates New Corporate Offices in Bridgewater

Lupin Limited recently commemorated the inauguration of its new corporate offices at 100 Somerset Corporate Blvd in Bridgewater.

16h

Corbus Pharmaceuticals Stock Slides on Pricing of Public Offering

Shares of Corbus Pharmaceuticals slid after the company priced its public offering at $13 a share. The stock declined 24% to $12.49 on Friday. Shares are down 22% in the past 12 months.

Just The News on MSN

Paxton sues pharmaceutical companies for 'deceptively marketing Tylenol to pregnant mothers'

"Big Pharma betrayed America by profiting off of pain and pushing pills regardless of the risks," Texas Attorney General Ken Paxton said

ZAWYA

PharmaJet signs distribution agreement with EVA Pharma

The signing follows the July 2025 Memo of Understanding (MOU) that was signed between PharmaJet, Egypt’s Unified Procurement Agency (UPA) and EVA Pharma, which outlined plans for how UPA could incorporate Tropis into its portfolio.

Vanda Pharmaceuticals Slides After Wider 3Q Loss, Tighter 2025 Revenue Forecast

Shares of Vanda Pharmaceuticals fell after the company reported a third-quarter loss that wider than a year ago and dropped the high end of its full-year revenue view. The stock was 18% lower, at $4.43, midday Thursday. The shares have fallen about 7.7% this year, but hit their 52-week high of $5.70 on Tuesday.